Aktis Oncology (AKTS) to Release Quarterly Earnings on Friday

Aktis Oncology (NASDAQ:AKTS) is expected to be issuing its Q1 2026 resultson Friday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $1.8120 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Aktis Oncology (NASDAQ:AKTS) last issued its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. On average, analysts expect Aktis Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aktis Oncology Stock Up 2.3%

Shares of NASDAQ:AKTS opened at $19.44 on Wednesday. The business’s 50 day simple moving average is $18.81. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $29.16.

Wall Street Analyst Weigh In

AKTS has been the subject of a number of recent analyst reports. TD Cowen started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target on the stock. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Bank of America began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Finally, HC Wainwright lifted their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $32.00.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.